Ferroptosis in cancer: revealing the multifaceted functions of mitochondria

Xinyi Ding, Lei Cui, Yanjun Mi, Jiachun Hu, Zheyou Cai, Qing Tang, Lin Yang, Zhuang Yang, Qingbing Wang, Hongsheng Li, Benxin Hou, Quentin Liu, Zhengzhi Zou, Yibing ChenCellular 2025 · DOI

TL;DR

This review positions mitochondria as the central command center for ferroptosis—an iron-dependent form of programmed cell death—rather than just a bystander. By orchestrating energy metabolism, iron storage, and reactive oxygen species (ROS) production, mitochondria provide multiple "vulnerability points" that can be exploited to kill drug-resistant cancer cells that have evolved to evade traditional apoptosis.

What Problem Does This Paper Address?

The primary hurdle in modern oncology is chemoresistance. Many tumors develop mutations that allow them to ignore "suicide" signals (apoptosis), leading to treatment failure and recurrence. Ferroptosis has emerged as a distinct, non-apoptotic death pathway characterized by the lethal accumulation of lipid peroxides (essentially, "rusting" of the cell membrane).

While early research focused on the cytoplasm, this paper addresses the growing realization that mitochondria are the "hub" of the metabolic processes required for ferroptosis. The authors synthesize recent findings to explain how mitochondrial dysfunction, iron handling, and metabolic shifts can be harnessed to bypass standard drug resistance, particularly in aggressive, mesenchymal-state cancer cells.

Methods

As a comprehensive review, the authors systematically analyze and synthesize over 200 recent studies (up to 2025) to map the molecular landscape of ferroptosis. They categorize the regulatory mechanisms into four primary axes:

  1. The Cyst(e)ine/GSH/GPX4 axis: The "classical" defense pathway.
  2. The FSP1-CoQ10 system: A secondary defense on the plasma membrane.
  3. The GCH1-BH4 pathway: A lipid-remodeling defense.
  4. The DHODH-CoQH2 system: A recently discovered, mitochondria-specific defense mechanism.

The paper specifically focuses on the interplay between mitochondrial dynamics (fusion/fission), mitophagy (the recycling of damaged mitochondria), and the organelle's role in iron and energy metabolism.

Datasets

Not discussed in the paper. (As a review article, it synthesizes existing literature rather than introducing new experimental datasets or benchmarks.)

Key Insights and Ideas

  • Mitochondria as the "Iron Hub": Mitochondria are the primary site for heme and iron-sulfur (Fe-S) cluster synthesis. The paper highlights that disrupting mitochondrial iron storage (via ferritinophagy) or transport (via VDACs) can flood the cell with "labile" iron, triggering the Fenton reaction and subsequent cell death.
  • The DHODH Defense: One of the most critical "aha" moments is the role of Dihydroorotate Dehydrogenase (DHODH). While GPX4 is the famous "master regulator" of ferroptosis in the cytoplasm, DHODH acts as a parallel defense system inside the mitochondria by reducing CoQ to CoQH2 to neutralize lipid peroxides.
  • Metabolic Vulnerability: Cancer cells typically prefer glycolysis (the Warburg effect). However, the paper notes that shifting a cell's metabolism toward oxidative phosphorylation (OXPHOS) actually increases its susceptibility to ferroptosis by ramping up mitochondrial ROS production.
  • EMT and Ferroptosis: Interestingly, cancer cells that have undergone Epithelial-Mesenchymal Transition (EMT)—the state most associated with metastasis and drug resistance—show a heightened dependence on ferroptosis-suppressive mechanisms, making them "exquisitely vulnerable" to GPX4 or DHODH inhibitors.
  • Dynamics and Mitophagy: The physical state of mitochondria matters. Mitochondrial fission (splitting) often promotes ferroptosis by releasing iron and ROS, while mitophagy (recycling) can either prevent or promote death depending on whether it's clearing damaged ROS-producers or releasing lethal amounts of stored iron.

Key Results

The review highlights several promising therapeutic strategies:

  • Synergistic Combinations: Combining ferroptosis inducers (like erastin or RSL3) with tyrosine kinase inhibitors (like lapatinib) has shown success in overcoming resistance in non-small cell lung cancer (NSCLC).
  • Mitochondria-Targeted Inducers: The authors discuss new compounds like B2 (a TPP-modified version of the DHODH inhibitor brequinar) that specifically target mitochondrial defenses, showing potent anti-tumor activity in melanoma models.
  • Morphological Markers: Ferroptosis is confirmed to be morphologically distinct from apoptosis; cells show shrunken mitochondria with increased membrane density and reduced cristae, but without the typical chromatin condensation seen in apoptosis.

Limitations and Future Work

The authors identify several critical gaps that remain:

  • Selectivity: The biggest challenge is achieving "precision ferroptosis"—triggering death in cancer cells without causing systemic toxicity in healthy tissues, particularly the brain and heart, which are sensitive to iron-mediated damage.
  • Mechanism Clarity: While many inducers are known, the exact molecular targets for some (like certain natural compounds) remain elusive.
  • The "Double-Edged Sword": Because ferroptosis is also linked to neurodegenerative diseases (Alzheimer’s, Parkinson’s), therapeutic induction must be carefully managed to avoid unintended side effects.
  • Future Direction: The field is moving toward developing more "mitochondria-targeted" delivery systems to increase the local concentration of ferroptosis-inducing agents within the tumor microenvironment.

Summary updated

Abstract

Ferroptosis is a programmed cell death characterized by iron-dependent lipid peroxidation, which is regulated by various cellular metabolic and signaling pathways. The main regulatory mechanisms of intracellular ferroptosis include the GSH-GPX4 pathway, the FSP1-CoQ10 pathway, the GCH1-BH4 pathway, and the DHODH-CoQH2 system. As the hub of iron metabolism and energy generation, mitochondria have been increasingly implicated in ferroptosis, underscoring their pivotal role in cellular processes. Ferroptosis is a significant mode of cell demise linked to cancer progression. It is expected to combat drug-resistant tumors by triggering iron-mediated cell death. This review delves into the intricate mechanisms governing intracellular ferroptosis, emphasizing the centrality of mitochondria in regulating this process within cancer cells. Furthermore, this review explores the potential and hurdles of targeting ferroptosis as a therapeutic avenue to overcome resistance to cancer treatment.
BibTeX
@inproceedings{ding2025ferroptosis,
  author = {Xinyi Ding and Lei Cui and Yanjun Mi and Jiachun Hu and Zheyou Cai and Qing Tang and Lin Yang and Zhuang Yang and Qingbing Wang and Hongsheng Li and Benxin Hou and Quentin Liu and Zhengzhi Zou and Yibing Chen},
  title = {{Ferroptosis in cancer: revealing the multifaceted functions of mitochondria}},
  booktitle = {Cellular},
  year = {2025},
  doi = {10.1007/s00018-025-05812-8},
}
Figure